Citations

Mayo Clinic

Clear

1883 citation(s) found for "Yu, Melissa".

Rotator Cuff Tendon Pathology Progression Over 2 Years In Manual Wheelchair Users With Spinal Cord Injury
Houde, Hannah Rose , VanStraten, Meegan, Wang, Jiefei , Murthy, Naveen S. , Morrow, Melissa M. , Morrow, Melissa M , Jahanian, Omid

Medicine & Science in Sports & Exercise | September 16, 2025 | Volume: 57 | Issue: 10S | Pages: 727-727

10.1249/01.mss.0001161168.05759.1f Get It

Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
Hirsch, Irl B., Kudva, Yogish C. , Blevins, Thomas , Raghinaru, Dan, Lum, John W. , Kollman, Craig, Pinsker, Jordan E. , Beck, Roy W. , Group*, 2IQP Study, Desjardins, Donna, Kurek, Corey, Kaur, Ravinder Jeet , Livingood, Daine, Rizvi, Shafaq , Graham, Timothy E., Terry, Adrienne, Luker, Ryan, Mellenthin, Melanie, Rezac, Stephanie, Liljenquist, David R., Rogers, Justin, Williams, Jonathan, Christensen, Rochelle, Lee, In‐Kyoung, Malone, Joann, Spanakis, Elias K. , Singh, Lakshmi G., Churchill, Jade, Comen, Kathleen, Scott, William H., Davis, Georgia M. , Arroyo, Lizda Guerrero, Oladejo, Omolade , Usman, Sabeena, Ahmann, Andrew , Schmid, Caleb, Dean, Ariel, Branigan, Deborah , Caswell, Brittany, Heyerman, Tess, Tessman, Brian, Vanderheide, Jnh, Dennis, Brittany , Hendricks, Lisa, Reyes-Rodriguez, Clemente, Wolf, Valerie, Coyne, Kasey, Kravarusic, Jelena, Fronczyk, Evelyn, Herrmann, Stefanie, Penn, Samsam C., Casaubon, Luis, Espinosa, Valerie, Pandit, Keta, Perez, Jennifer, Stewart, Ana, Assir, Courtney, Fields, Cory, Kruger, Davida , Estrada, Kathleen, Jones, J. Kimberly, Mukhashen, Shereen, Corker, Natalie, Hunter, Heather, Layton, Paula, Brown, Sue A. , Afreen, Samina , Dhillon, Jasmeen, Emory, Emma, Fulkerson, David, Fuller, Morgan, Holmes, Viola, Kollar, Laura, Toole, Elyse, Levister, Camilla, O’Malley, Grenye , Ipek, Aslihan, Alabi, Denise, Ellis, Emily, Hassan, Shaziah, Ogyaadu, Selassie, Tamarez, Denisa, Weinstock, Ruth S. , Stone, Sheri , Bzdick, Suzan, Agostini, Lynn, Bulger, Jane , Wolpert, Howard , Atakov-Castillo, Astrid , Sullivan, Asya, Aia, Corinne, Brouillard, Elizabeth, Driscoll, Marsha, Lapier, Heather, Payra, Sherryl, Vancer, Louise, Averkiou, Xenia, Baran, Jesica, Holod, Rosanna, Litvicov, Patrisia, Mandava, Patali, Swinton, Sydney, Khakpour, Dori , Broyles, Frances E. , Marks, Sheryl, Mitchell, Tina, Hairston, Babette, Costello, Reilly, Curtis, Stella, Rickels, Michael R., Kamimoto, Jorge Jo, Peleckis, Amy J. , Sultan, Rahaf , Dalton-Bakes, Cornelia, Bourne, Patricia, Haidar, Ahmad, Pasqua, Melissa, Tardio, Vanessa , Moore, Adelyn, Kemp, Gabrielle, Raskin, Philip, Jordan, L.F., Shao, Baomei, DoNguyen, Trang, Meeks, Tram, Phan, Michael , Lesniak, Amanda, Becerra, Mario, Denallo, Erica, Lewis, Claudia , Tribout, Jerry, Tribout, Megan, DiFrancesco, Kathryn, Phillips, Kylie, Lum, John W., Campos, Tiffany, Morrell, Beth, Oduah, Vanessa, Cardenas-Villamil, Gabriela, Morales, Amanda, Murphy, Carlos, Strayer, Heidi, Spanbauer, Charles , Kollman, Craig, Sasson-Katchalski, Ravid, Piquette, Nicole, Wheatcroft, Alex, WHITE, KIRSTIN N., Carmelo, KC, Janicek, Robert, Gabrielson, Deanna, Mercado, Kevin, Hirsch, Irl B. , Pinsker, Jordan E , Beck, Roy W , Hirsch, Irl B , Ahn, David , Rickels, Michael R. , Group*, 2IQP Study, Smith, Joshua W. , Christensen, Rochelle, Malone, Joann, Pasquel, Francisco J. , Tajrishi, Farbod Zahedi , Arroyo, Lizda Guerrero, Dean, Ariel, Howard, Matthew, Vander-Heide, Jesse, Aleppo, Grazia , Fields, Cory, Layton, Paula, Oliveri, Mary Clancy , Levy, Carol J. , Agostini, Lynn, Steenkamp, Devin W , Spaic, Tamara , Liu, Selina , Marks, Sheryl, Mitchell, Tina, Costello, Reilly, Curtis, Stella, Rickels, Michael R., Bourne, Patricia, Tsoukas, Michael A. , Pasqua, Melissa-Rosina , Moore, Adelyn, Kemp, Gabrielle, Meeks, Tram, Phan, Michael, Hatipoğlu, Betül , Lesniak, Amanda, Bellini, Natalie J. , Howard, Quiana , Lewis, Claudia, DiFrancesco, Kathryn, Lum, John W., Morrell, Beth, Morales, Amanda, Kanapka, Lauren , Kollman, Craig, Le, Hung V.

Diabetes Care | September 15, 2025 | Volume: 48 | Issue: 12 | Pages: 2061-2066

10.2337/dc25-1125 | PMID 40953318 Get It

OBJECTIVE The Centers for Medicare & Medicaid Services (CMS) requires a low C-peptide level for insulin pump coverage unless the individual is β-cell autoantibody positive, which precludes coverage of automated insulin delivery (AID) systems for many people with type 2 diabetes. RESEARCH DESIGN AND METHODS In the Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy study evaluating the t:slim X2 insulin pump with Control-IQ+ technology, adults with insulin-treated type 2 diabetes were categorized into high C-peptide (n = 195) and low C-peptide (n = 59) groups based on CMS criteria. RESULTS In the AID group, mean HbA1c decreased from baseline by 0.8%, which was significantly greater than in the control group with both high (P < 0.001) and low (P = 0.02) C-peptide levels. Results were similar in participants ≥65 years old. CONCLUSIONS The benefit of AID is present with high and low C-peptide levels. Thus, requiring a low C-peptide level as a prerequisite for AID therapy is not warranted.
Adverse Reactions to Phenol Neurolysis: Report of Severe Necrosis and Infection Following Genicular Nerve Ablation
Morodomi, Michael D, Cortes, Melissa P. , Smerina, Michael , Gavrancic, Tatjana , Pagán, Ricardo J. , Khanijo, Aditya , Gopikrishnan, Nilaa, Baptista, Aleksandra Murawska , Dumitrascu, Adrian G, Khanijo, Aditya A, Dumitrascu, Adrian

Clinical Case Reports | September 13, 2025 | Volume: 13 | Issue: 9 | Pages: No page available

10.1002/ccr3.70885 | PMID 40948702 Get It

ABSTRACTThis report details a severe complication of phenol neurolysis in a diabetic patient, where phenol induced tissue necrosis can lead to severe cellulitis with ulceration that may prove difficult to treat. It emphasizes the importance of considering comorbidities when selecting phenol neurolysis for treatment of chronic pain.
A Cross‐Sectional Analysis of Social Determinants of Health in Bipolar Disorder: Exploring Gender‐Related Differences
Gardea‐Resendez, Manuel , Fuentes‐Salgado, Manuel, Romo‐Nava, Francisco , Prieto, Miguel L. , Bond, David J. , Betcher, Hannah K. , Moore, Katherine M. , Solares‐Bravo, Melissa , Ercis, Mete , Miola, Alessandro , Taylor-Desir, Monica , Frye, Mark A. , Solares-Bravo, Melissa , Ercis, Mete , Miola, Alessandro , Sanchez-Ruiz, Jorge A , Singh, Balwinder , Biernacka, Joanna , Taylor-Desir, Monica J., Frye, Mark , Romo-Nava, F , Bond, David J , Gardea-Resendez, Manuel , Özerdem, Ayşegül , Sánchez-Ruiz, Jorge A. , Veldić, Marin , Singh, Balwinder , Cuéllar‐Barboza, Alfredo B. , Coombes, Brandon J. , Biernacka, Joanna M. , McElroy, Susan L.

Bipolar Disorders | September 12, 2025 | Volume: 27 | Issue: 8 | Pages: 545-550

10.1111/bdi.70062 | PMID 40936288 Get It

ABSTRACT Objectives To explore the clinical impact of social determinants of health (SDoH) stress in bipolar disorder (BD) course of illness and to explore potential gender differences in SDoH stress endorsement. Methods 2280 individuals living with BD type I or II (62% women; 67.5% BD‐I) participating in the Mayo Clinic Bipolar Biobank who completed a questionnaire assessing positive and negative‐valent stressors in the 12 months prior to study enrollment were included for this analysis. Six negative stressors were used as proxies of SDoH. Generalized linear models were used to test the association between SDoH stressors and markers of illness severity as well as potential differences by sex by including an interaction term. Results After adjusting for age, sex, and recruitment site, SDoH‐related stressors were significantly associated with a more severe course of illness in both men and women. Except for unemployment rates, women reported more frequently SDoH‐related stress (i.e., lack of family support, financial problems, health coverage and access problems). Conclusions The study found significant gender differences in both the endorsement of specific SDoH stressors and in the prevalence of specific illness severity markers; however, it did not directly test the predictive relationship between gender differences in SDoH and illness severity markers. Future studies aiming to achieve health equity in mental health care should continue assessing social determinants of health stressors, incorporating a gender perspective to better understand their influence on bipolar disorder.
Genetically determined body mass index is associated with diffuse large B‐cell lymphoma in polygenic and Mendelian randomization analyses
Moore, Amy , Teras, Lauren R. , Machiela, Mitchell J. , Arias, Joshua , Monnereau, Alain , Wang, Zhaoming , Vermeulen, Roel , Smedby, Karin E. , Spinelli, John J., Nieters, Alexandra , Bracci, Paige M. , Camp, Nicola J. , Hjalgrim, Henrik, Adami, Hans‐Olov , Albanes, Demetrius, Becker, Nikolaus, Benavente, Yolanda , Clavel, Jacqueline , Curtin, Karen , Ghesquières, Hervé, Glimelius, Bengt, Lan, Qing , Liebow, Mark , McKay, James , Offit, Kenneth, Padoan, Marina, Patel, Alpa V. , Ríboli, Elio , Severson, Richard K., Tinker, Lesley F. , Weinstein, Stephanie J. , Zheng, Tongzhang, Chanock, Stephen J., Rothman, Nathaniel , Berndt, Sonja I. , Teras, Lauren R , Wang, Zhaoming , Vajdic, Claire M , De Vivo, Immaculata , Boffetta, Paolo , Brooks-Wilson, Angela R , Canzian, Federico , Southey, Melissa C , Cerhan, James R , Berndt, Sonja I , Clavel, Jacqueline , Machiela, Mitchell J , Riboli, Elio , Kane, Eleanor , Panagiotou, Orestis A. , Doo, Nicole Wong , Slager, Susan L. , Vajdic, Claire M. , Vijai, Joseph , Giles, Graham G. , Link, Brian K. , Arslan, Alan A. , Salles, Gilles , Cozen, Wendy , Vivo, Immaculata De , Albanes, Demetrius , Bisanzi, Simonetta , Brennan, Paul E. , Brooks‐Wilson, Angela , Canzian, Federico , Conde, Lucía , Cox, David G. , Foretová, Lenka , Glimelius, Bengt , Habermann, Thomas M. , Hofmann, Jonathan N. , Lan, Qing , Lincoln, Anne , Maynadié, Marc , Melbye, Mads , Miligi, Lucia , Milne, Roger L. , Molina, Thierry Jo , Morton, Lindsay M. , North, Kari E. , Offit, Kenneth, Piro, Sara , Purdue, Mark P. , Ravichandran, Vignesh , Southey, Melissa C. , Staines, Anthony , Travis, Ruth C. , Wang, Sophia , Weiderpass, Elisabete , Rothman, Nathaniel , Birmann, Brenda M. , Cerhan, James R.

International Journal of Cancer | September 5, 2025 | Volume: 158 | Issue: 1 | Pages: 45-59

10.1002/ijc.70039 | PMID 40910475 Get It

Abstract Obesity has been associated with non‐Hodgkin lymphoma (NHL), but the evidence is inconclusive. We examined the association between genetically determined adiposity and four common NHL subtypes: diffuse large B‐cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma, using eight genome‐wide association studies of European ancestry ( N = 10,629 cases, 9505 controls) and constructing polygenic scores for body mass index (BMI), waist‐to‐hip ratio (WHR), and waist‐to‐hip ratio adjusted for BMI (WHRadjBMI). Higher genetically determined BMI was associated with an increased risk of DLBCL [odds ratio (OR) per standard deviation (SD) = 1.18, 95% confidence interval (95% CI): 1.05–1.33, p = .005]. This finding was consistent with Mendelian randomization analyses, which demonstrated a similar increased risk of DLBCL with higher genetically determined BMI (OR per SD = 1.12, 95% CI: 1.02–1.23, p = .03). No significant associations were observed with other NHL subtypes. Our study demonstrates a positive link between a genetically determined BMI and an increased risk of DLBCL, providing additional support for increased adiposity as a risk factor for DLBCL.
A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis
Striebich, Christopher C. , Feser, Marie L. , O’Dell, James R., James, Judith A. , Sparks, Jeffrey A. , Davis, John M. , Graf, Jonathan , McMahon, Maureen , Solow, E. Blair , Forbess, Lindsy, Tiliakos, Athan, Schiopu, Elena , Horowitz, Diane , Strickland, C. , Arriens, Cristina , Grossman, Jennifer M. , Frazer‐Abel, Ashley , Fleischer, Chelsie , Greenleaf, Melissa E., York, Kate, Walker, Sarah , Keyes‐Elstein, Lynette, Byron, M., Goldmuntz, Ellen, Holers, V. Michael , Deane, Kevin D , James, Judith A , Sparks, Jeffrey A , Davis, John M , McMahon, Maureen , Kay, Jonathan , Fedler, Janel , Holers, V Michael , Tiliakos, Athan, Danila, Maria I. , Guthridge, Joel M. , Demoruelle, Mary Kristen , Bemis, Elizabeth A. , Fox, David A. , Mikuls, Ted R. , Walker, Sarah, Keyes-Elstein, Lynette

Arthritis & Rheumatology | August 30, 2025 | Volume: 78 | Issue: 4 | Pages: 809-820

10.1002/art.43366 | PMID 40884017 Get It

Objective Individuals with serum elevations of anti–cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such at‐risk individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence. Methods In this phase 2 randomized trial, individuals at risk for RA with anti‐CCP3 ≥2 times the upper limit of normal (ULN) were assigned to receive HCQ or placebo for 12 months, with up to 24 months of postdrug follow‐up. The primary outcome was the development of clinical RA, as defined in the protocol, at 36 months. Secondary outcomes included safety, development of inflammatory arthritis (IA), and participant‐reported joint symptoms. Results Of 144 randomized participants, 71 were assigned to HCQ and 73 to placebo. In the modified intent‐to‐treat population, clinical RA occurred in 21 of 69 (30.4%) participants in the HCQ group and 24 of 73 (32.9%) in the placebo group. The risk of clinical RA at 36 months was 0.336 with HCQ and 0.394 with placebo (difference −0.058; 95% confidence interval −0.336 to 0.220; P = 0.52). Results for IA were similar. The occurrence and severity of joint symptoms were not observed to differ between groups. Adverse event incidence was similar between groups. Conclusion In this trial involving individuals with anti‐CCP3 levels ≥2 times the ULN, 12 months of HCQ did not prevent the development of clinical RA at 36 months. image
First Use of Phage Therapy in Canada for the Treatment of a Life-Threatening, Multidrug-Resistant Staphylococcus epidermidis Periprosthetic Joint Infection
Cammuso, Melissa Teresa, Cook, Bradley W. M. , Cameron, D. William , Tamayo, Marielou, Peters, Melissa J. , Arnaud, Tia, Lau, S. , Almblad, Henrik , Fournier, Nicolas , LoVetri, Karen, Lightly, Tasia Joy , Chung, Yuen Ming, Roy, Riya , Theriault, Natasha, Theriault, Steven, Suh, Gina A. , Azad, Marisa Ann , Peters, Melissa J , Almblad, Henrik , Suh, Gina A , Azad, Marisa , Ryan, Stephen J. , Arnaud, Tia, Roy, Riya

Viruses | August 14, 2025 | Volume: 17 | Issue: 8 | Pages: 1118

10.3390/v17081118 | PMID 40872831 Get It

We describe the first use of phage therapy in Canada for the treatment of a life-threatening periprosthetic joint infection (PJI), with successful outcome. PJI is a devastating complication of joint replacement surgery, with high morbidity and mortality. Our patient presented with early sepsis from a chronic recalcitrant multidrug-resistant (MDR) Staphylococcus epidermidis hip PJI which had repeatedly failed standard therapy. She had previously undergone 10 operations of the right hip, and only three weeks after completing a prolonged course of daptomycin following her most recent hip revision, she developed a draining sinus tract. Given the high burden of disease, inability to achieve surgical source control, and lack of antibiotic treatment options for long-term suppressive therapy, bacteriophage (phage) therapy was pursued. The patient underwent irrigation and debridement with complex flap reconstruction: intraoperative tissue cultures again yielded MDR S. epidermidis. We developed a novel phage therapy protocol for this patient, with twice daily, intra-articular and intravenous (7 × 109 PFU/dose) phage delivery over a planned 14-day course. Complete healing of the wound with cessation of drainage occurred within one month after treatment. A marked improvement in right hip pain and mobility occurred within three months after treatment. Twelve months following phage treatment, there is normalization of serum inflammatory markers with diminished pain, increased mobility, and no recurrent surgery. Our patient continues to improve and is currently living independently at home, with sustained clinical control of infection.
Caregiver experiences after the death of a person with dementia with Lewy bodies: A mixed-methods analysis
Armstrong, Melissa J. , Dai, Yunfeng , LaBarre, Brian , Wang, Tingchang , Sovich, Kaitlin , Jury, Hannah F , Henriquez, Adolfo M , Maixner, Susan M. , Paulson, Henry L. , Fields, Julie A. , Lunde, Angela , Manning, Carol A. , Taylor, Angela , Dai, Yunfeng , LaBarre, Brian , Wang, Tingchang , Jury, Hannah F , Henriquez, Adolfo M , Maixner, Susan M , Lunde, Angela M , Boeve, Brad , Baker, Zachary G , Paulson, Henry L , Armstrong, Melissa J , Wollney, Easton N. , Li, Zhigang , Galvin, James E. , Boeve, Bradley F.

Journal of Alzheimer’s Disease | August 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13872877251365218 | PMID 40808538 Get It

Background Dementia with Lewy bodies (DLB) is a common degenerative dementia, but no studies investigate bereaved caregiver experiences. Objective To investigate the experiences of caregivers three months after the death of persons with DLB using a mixed-methods approach. Methods Dyads of individuals with moderate-advanced DLB and their primary informal caregivers were followed prospectively every 6 months until the person with DLB died. Caregivers completed a study visit with questionnaires and a semi-structured interview ∼3 months later. Spearman correlation coefficients and Wilcoxon rank-sum tests evaluated the relationships of post-death measures with pre-death patient and caregiver variables. Thematic analysis was used to analyze the interviews. Results Seventy-three caregivers completed visits (mean 3.5 months post-death). Most of the caregivers were women (82.2%) and spouses (76.7%) or adult children (17.8%). Over 40% had scores indicating risk for clinical depression. Post-death caregiver experiences (depression, quality of life, grief, resilience) correlated with pre-death caregiver experiences. Post-death experiences did not associate with patient characteristics, disease-related symptoms, or healthcare services used in the last 6 months of life. Trajectories for caregiver measures from pre- to post-death visits varied widely. Interview themes included grief and sadness, anger, guilt and regret, relief, appreciation/gratitude, and adjusting to a new normal. Conclusions The finding that pre-death caregiving experiences have the strongest association with post-death experiences emphasizes the critical importance of accessible and evidence-based caregiver support before and after the death of a person with DLB. Research is needed to develop interventions for current and bereaved caregivers of individuals with DLB. Trial registration information NCT04829656 (submitted 2021-03-22).
Feasibility and Acceptability of Virtual Dignity Therapy for Palliative Care Patients With Advanced Cancer
Weng, Jessica , Wild, Ellen, Rhee, Laura, Piderman, Katherine M. , Santiago, Abraham Labrada, Rinker, Caila J., Felt, Melissa, Ingram, Cory , Pachman, Deirdre R. , Weng, Jessica , Chesak, Sherry S. , Santiago, Abraham Labrada, Rinker, Caila, Fischer, Karen M.

American Journal of Hospice and Palliative Medicine® | August 8, 2025 | Volume: 43 | Issue: 9 | Pages: 940-947

10.1177/10499091251361467 | PMID 40778740 Get It

Background Patients with advanced cancer experience a substantial amount of existential and emotional distress. Dignity therapy (DT) is a brief, individualized psychotherapy that aims to relieve existential distress and improve the experiences of individuals impacted by serious illness. Aim To evaluate the feasibility and acceptability of virtual DT (vDT) among patients with advanced cancer. Methods This pilot study recruited adult patients with advanced cancer and an expected prognosis >6 months. The vDT intervention consisted of 2 sessions of guided interviews focused on life review, discussion, and development of a generativity document (GD). Feasibility and acceptability were assessed quantitatively and with semi-structured interviews. Effectiveness measures (distress, dignity impact scale, quality of life [QOL]) were administered pre/post intervention. Results Thirty-one patients referred from a palliative care clinic were eligible. Twenty-one consented and 15 received a final GD. Patients who completed final assessments (N = 9) reported satisfaction with their experience and would recommend the therapy to others. Patients found the virtual component of the intervention acceptable, and the majority noted an improvement in their dignity. Qualitative analysis revealed themes of study team effectiveness, perspectives on intervention processes, benefits to self, and benefits to loved ones. Conclusion Participation in vDT intervention was feasible and acceptable for patients. Patients appreciated the connection with the interviewer, the process, and the benefit of having a document to share with loved ones. Preliminary effectiveness data suggest vDT improves sense of dignity.
Colorectal cancer screening barriers, facilitators, and promotion recommendations by Alaska Native people who are non‐adherent to colorectal cancer screening
Toffolon, Melissa, Jeffries, Lauren , Bailie, Danika, Rutten, Lila Finney, Kisiel, John, Redwood, Diana , Flanagan, Christie A. , Jeffries, Lauren, Kisiel, John B.

The Journal of Rural Health | August 6, 2025 | Volume: 41 | Issue: 3 | Pages: No page available

10.1111/jrh.70067 | PMID 40765125 Get It

Abstract Purpose We examined barriers and facilitators to colorectal cancer (CRC) screening among Alaska Native individuals who had never been screened or were not up to date with screening guidelines. Methods As part of a larger study investigating the use of the multitarget stool DNA test in rural Alaska communities, we conducted focus groups and in‐depth interviews with 28 never screened or not up‐to‐date Alaska Native people in two remote communities between November 2022 and July 2023. Participants shared their barriers to CRC screening and offered suggestions to improve programs to better reach those who are guideline discordant. Findings General screening barriers included lack of knowledge, fear of discovering you have cancer, and cultural health beliefs. Colonoscopy‐specific barriers included embarrassment from knowing the local medical staff, having rectal area viewed or touched, fear of pain and injury, difficulty scheduling a procedure due to traditional food gathering activities, lack of provider referrals/reminders, and the high cost of air travel required to get to a colonoscopy facility. Stool DNA‐specific concerns included not feeling that it was as good as colonoscopy, lack of privacy to do the test, and hesitancy collecting stool samples. Suggestions for increasing screening rates included increasing access via paid air transportation, using local indigenous languages, improving provider relationships and reminder systems, and providing CRC and screening education using trusted messengers. Conclusions This was the first exploration of the perceptions of CRC screening among guideline discordant Alaska Native people. Identified themes can be used to improve screening program outreach effectiveness in the future.